Pouchitis Clinical Trial
Official title:
A Randomized, Double-Blind, Placebo-Controlled Phase 4 Study to Evaluate the Efficacy and Safety of Entyvio (Vedolizumab IV) in the Treatment of Chronic Pouchitis (EARNEST)
The purpose of this study is to compare the efficacy of vedolizumab intravenous (IV) and placebo in terms of the percentage of participants with chronic or recurrent pouchitis achieving clinically relevant remission.
Vedolizumab is being tested to treat people who have chronic pouchitis. This study will look at the healing of inflammation of ileal pouch in people who take vedolizumab as compared to those receiving a matching placebo. The study will enroll approximately 110 patients. Participants will be randomly assigned to one of the two treatment groups-which will remain undisclosed to the patient and study doctor during the study (unless there is an urgent medical need): - Vedolizumab 300 mg IV - Placebo IV All participants will receive an intravenous infusion at Day 1, Weeks 2, 6, 14, 22, and 30 along with concomitant antibiotic treatment with ciprofloxacin 500 mg twice daily through Week 4. This multicenter trial will be conducted in North America and Europe. The overall time to participate in treatment and efficacy assessment of this study is 34 weeks. Participants will make multiple visits to the clinic, plus a final visit 18 weeks after the last dose of study drug for a safety follow-up assessment (up to Week 48). Participants will also participate in a long-term follow-up, by phone after the last dose of study drug up to Week 56. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Recruiting |
NCT04979832 -
GM-CSF, Fosfomycin and Metronidazole for Pouchitis in Ulcerative Colitis Patients After Restorative IPAA Surgery
|
Phase 1/Phase 2 | |
| Terminated |
NCT00061282 -
Clotrimazole Enemas for Pouchitis in Children and Adults
|
Phase 1/Phase 2 | |
| Not yet recruiting |
NCT05829109 -
Fecal Microbiota Transplant for Patients With Chronic Pouchitis
|
Early Phase 1 | |
| Recruiting |
NCT03136419 -
Microbiota and Immune microEnvironment in Pouchitis
|
N/A | |
| Withdrawn |
NCT04640155 -
Treating Chronic Pouchitis With a Low FODMAP Diet
|
N/A | |
| Completed |
NCT02201186 -
To Determine the Effect of Honey Enema in the Treatment of Patients With Acute Pouchitis
|
Phase 2 | |
| Not yet recruiting |
NCT01202396 -
The Interaction Between Intestinal Microbiota, Innate Defense and Epithelial Integrity in the Development of Pouchitis
|
N/A | |
| Completed |
NCT02428361 -
Fecal Microbiota Transplant (FMT) for Pouchitis
|
Early Phase 1 | |
| Completed |
NCT03538366 -
Fecal Microbiota Transplantation for Chronic Pouchitis
|
N/A | |
| Completed |
NCT04763564 -
Efficacy of Liraglutide Therapy in Patients With IPAA
|
Phase 2 | |
| Terminated |
NCT00583531 -
Safety and Efficacy of AST-120 in the Treatment of Antibiotic-Refractory Pouchitis
|
Phase 2 | |
| Recruiting |
NCT03524352 -
the Prophylaxis of Recurrent Pouchitis After Fecal Microbiota Transplant in UC With Ileo-anal Anastomosis
|
Phase 3 | |
| Completed |
NCT04820413 -
Faecal Microbiota Transplantation From Normal Pouch Function Donor in the Treatment of Chronic Pouchitis
|
N/A | |
| Recruiting |
NCT04089345 -
Stelara fOr ChRonic AntibioTic rEfractory pouchitiS
|
Phase 3 | |
| Not yet recruiting |
NCT03526796 -
Hyperbaric Oxygen Therapy for Antibiotic Refractory Pouchitis
|
N/A | |
| Terminated |
NCT02782325 -
Safety and Efficacy of Fecal Microbiome Transplantation (FMT) in the Treatment of Antibiotic Dependent Pouchitis (ADP)
|
Phase 1/Phase 2 | |
| Completed |
NCT02828410 -
Nutritional Impact of Serum-Derived Bovine Immunoglobulin Protein Isolate in Subjects With IPAA
|
N/A | |
| Recruiting |
NCT05578313 -
Inflammatory Bowel Diseases (IBD) Cannabis Registry
|
||
| Not yet recruiting |
NCT06316999 -
Intestinal Ultrasound for the Evaluation of Pouchitis and Other Outcomes After Ileal Pouch-Anal Anastomosis
|
N/A | |
| Terminated |
NCT04100291 -
Faecal Microbiota Transplantation in the Treatment of Chronic Pouchitis
|
N/A |